QLS5133, a Novel CDH6-Targeting ADC from Qilu Pharmaceutical, Receives First Clinical Approval in China for Advanced Solid Tumors

Recently, the CDE official website showed, Qilu PharmaceuticalQLS5133 for Injection Approved for Clinical Use in Advanced Solid Tumors. This is Qilu Pharmaceutical.The 3rd ADC Drug Approved for Clinical Trials。

Source: CDE Official Website

QLS5133 is an ADC drug targeting CDH6,Based on Qilu's independently developed new topoisomerase-1 （TOPO 1）Inhibitor QLS6917 platform, developed through site-specific conjugation technology with a DAR value of 8.

Source: AACR 2025

Qilu Pharmaceutical Co., Ltd. Announced at the 2025 AACR ConferenceQLS513Clinical pre-data of 3, the results show.Compared with DS-6000a, QLS5133 exhibited higher affinity and internalization rate. In multiple xenograft studies involving CDH6-expressing human cancer cell lines of ovarian cancer and renal cell carcinoma, treatment with QLS5133 significantly induced tumor regression.

Insight database shows that currently globally there are6 CDH6 ADCs Under Research, with 5 products entering the clinical stage.

Source: Insight Database

Cover Source:Corporate Logo

Disclaimer:This article is for information sharing only, and does not represent the position or viewpoint of Insight. It does not recommend or introduce any treatment plans. If you have any needs, please consult and contact正规医疗机构.

Editor: Crescent

PR Article Collaboration: WeChat insightxb